Altamira Therapeutics Ltd.
NASDAQ: CYTO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Meyer
- Employees
- 10
- Headquarters
- Hamilton, Bermuda
- IPO year
- 2014
- Market cap
- $1.1M
- Website
- https://altamiratherapeutics.com
Loading CYTO…
Loading profile data…Frequently asked questions about CYTO
What does Altamira Therapeutics Ltd. (CYTO) do?
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in...
Where does CYTO trade?
Altamira Therapeutics Ltd. (CYTO) trades on the NASDAQ Capital Market.
What sector is CYTO in?
Altamira Therapeutics Ltd. (CYTO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Altamira Therapeutics Ltd.?
Thomas Meyer is the chief executive officer of Altamira Therapeutics Ltd. (CYTO).
Where is Altamira Therapeutics Ltd. headquartered?
Altamira Therapeutics Ltd. is headquartered in Bermuda.
Does CYTO pay a dividend?
Altamira Therapeutics Ltd. (CYTO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYTO go public?
Altamira Therapeutics Ltd. (CYTO) completed its initial public offering in 2014.